{
  "documentMetadata": {
    "title": "Pneumonia, Hospital-Acquired",
    "lastUpdated": "2025-01-08",
    "sourceFile": "Pneumonia, Hospital-Acquired.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Empiric therapy for hospital-acquired pneumonia.",
        "Pneumonia with onset 48 hours after hospital admission.",
        "Recommendations based on 2016 IDSA treatment guidelines (Clin Infect Dis 63:e61, 2016).",
        "Often associated with patients on mechanical ventilation (see ventilator-associated pneumonia for specific treatment recommendations)."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Early-onset: <5 days in the hospital, no other risk factors for multidrug-resistant (MDR) organisms"
        },
        {
          "type": "list",
          "items": [
            "Strep. pneumoniae",
            "Staph. aureus",
            "H. influenzae",
            "Enteric gram-negative bacilli"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Late-onset: â‰¥5 days in the hospital, risk factors for MDR organisms present"
        },
        {
          "type": "list",
          "items": [
            "Staph. aureus (often MRSA)",
            "Gram-negative enterics often multi-drug resistant (MDR). The following (ESKAPE) pathogens were etiology in nearly 80% of patients: Curr Opin Pulm Med 20:252, 2014.",
            "Escherichia coli",
            "Serratia marcescens",
            "Klebsiella pneumoniae",
            "Acinetobacter baumannii",
            "Pseudomonas aeruginosa",
            "Enterobacter sp."
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Possible role of viruses"
        },
        {
          "type": "list",
          "items": [
            "In non-ventilated hospital acquired pneumonia, film array multiplex PCR detected respiratory virus (rhinovirus, influenza, parainfluenza most often) in 22.4%. Unclear whether concomitant bacterial infection: Respiratory Medicine 2017;122:76",
            "In study of patients with ventilator-associated pneumonia, 22.5% had respiratory virus (RSV or parainfluenza) in the airway: Am J Respir Crit Care Med 2012;186:325."
          ]
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "appliesTo": {
          "description": "Low risk of MRSA (prevalence <10-20%), no risk factors for MDR pathogens",
          "criteria": [
            {
              "parameter": "risk factor",
              "value": "Low risk of MRSA (prevalence <10-20%), no risk factors for MDR pathogens"
            }
          ]
        },
        "components": [
          {
            "drug": "Cefepime",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q8h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "appliesTo": {
          "description": "Low risk of MRSA (prevalence <10-20%), no risk factors for MDR pathogens",
          "criteria": [
            {
              "parameter": "risk factor",
              "value": "Low risk of MRSA (prevalence <10-20%), no risk factors for MDR pathogens"
            }
          ]
        },
        "components": [
          {
            "drug": "Piperacillin-tazobactam",
            "dose": "4.5 gm",
            "route": "IV (over 4 hr)",
            "frequency": "q8h"
          }
        ],
        "notes": "see drug page for comment on loading dose"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "appliesTo": {
          "description": "Low risk of MRSA (prevalence <10-20%), no risk factors for MDR pathogens",
          "criteria": [
            {
              "parameter": "risk factor",
              "value": "Low risk of MRSA (prevalence <10-20%), no risk factors for MDR pathogens"
            }
          ]
        },
        "components": [
          {
            "drug": "Meropenem",
            "dose": "1 gm",
            "route": "IV",
            "frequency": "q8h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "appliesTo": {
          "description": "Low risk of MRSA (prevalence <10-20%), no risk factors for MDR pathogens",
          "criteria": [
            {
              "parameter": "risk factor",
              "value": "Low risk of MRSA (prevalence <10-20%), no risk factors for MDR pathogens"
            }
          ]
        },
        "components": [
          {
            "drug": "Levofloxacin",
            "dose": "750 mg",
            "route": "IV/po",
            "frequency": "q24h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "suspected MRSA (i.e., MDR risk factor, known prior MRSA infection or colonization or positive NAAT)",
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q8-12h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "appliesTo": {
          "description": "More severe disease, i.e., sepsis, hypotension, rapid progression of infiltrates on chest radiograph indicating high risk of mortality; MDR risk factor, MRSA prevalence >10-20%",
          "criteria": [
            {
              "parameter": "severity",
              "value": "More severe disease, i.e., sepsis, hypotension, rapid progression of infiltrates on chest radiograph indicating high risk of mortality"
            },
            {
              "parameter": "risk factor",
              "value": "MDR risk factor, MRSA prevalence >10-20%"
            }
          ]
        },
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q8-12h"
          },
          {
            "drug": "Cefepime",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q8h",
            "connector": "+"
          },
          {
            "drug": "Piperacillin-tazobactam",
            "dose": "4.5 gm",
            "route": "IV (over 4 hr)",
            "frequency": "q8h",
            "connector": "or"
          },
          {
            "drug": "Meropenem",
            "dose": "1 gm",
            "frequency": "q8h",
            "connector": "or"
          }
        ],
        "notes": "See pip-tazo drug page for comment on loading dose."
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "Legionella suspected",
        "components": [
          {
            "drug": "Levofloxacin",
            "dose": "750 mg",
            "route": "po/IV",
            "frequency": "q24h"
          },
          {
            "drug": "Azithromycin",
            "dose": "500 mg",
            "route": "IV",
            "frequency": "q24h",
            "connector": "or"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "Pseudomonas suspected, high risk of mortality, or MDR Gram-negative suspected",
        "components": [
          {
            "drug": "Ciprofloxacin",
            "dose": "400 mg",
            "route": "IV",
            "frequency": "q8h"
          },
          {
            "drug": "Levofloxacin",
            "dose": "750 mg",
            "route": "IV",
            "frequency": "q24h",
            "connector": "or"
          },
          {
            "drug": "Tobramycin",
            "dose": "5-7 mg/kg",
            "route": "IV",
            "frequency": "q24h",
            "connector": "or"
          },
          {
            "drug": "Amikacin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q24h",
            "connector": "or"
          }
        ],
        "notes": "add to increase likelihood that at least one drug will be active"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Linezolid 600 mg IV q12h can be substituted for Vancomycin.",
        "Aztreonam 2 gm IV q8h instead of cefepime, piperacillin-tazobactam, or meropenem for patients with hypersensitivity to beta-lactams, however, unlike these other agents aztreonam is not active against Gram-positive organisms, S. aureus in particular and should add vancomycin pending culture results.",
        "Ceftolozane-tazobactam 3 g IV q8h covers pseudomonas and ESBL-producing Enterobacteriaceae (Lancet Infect Dis 2019 Dec;19(12):1299-1311).",
        "For suspected carbapenem-resistant Enterobacterales infection: can substitute Ceftazidime-avibactam 2.5 gm IV infused over 2 hours q 8h for Cefepime, Piperacillin-tazobactam or Meropenem (does not cover metallo-beta-lactamase producing organisms)",
        "Imipenem-cilastatin-relebactam 1.25 gm IV infused over 30 minutes q6h or Meropenem-vaborbactam 4 gm IV infused over 3 hr q8h are also options (neither agent covers metallo-beta-lactamase producing organisms).",
        "For more detail information on multiple-drug resistant Gram-negatives click here"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "If S. aureus nares screen is negative for MRSA no need to empirically cover for MRSA, and if coverage initiated, de-escalation is safe with a negative predictive value of 96.1% (Clin Infect Dis 2019 Oct 1. pii: ciz974. doi: 10.1093/cid/ciz974).",
        "Duration of therapy",
        "In general treat for 7-8 days",
        "Whether a longer duration of therapy should be used for pneumonia caused by non-fermenting organisms (e.g., Pseudomonas aeruginosa) or multiple-drug resistant Gram-negatives continues to be debated (See Clin Infect Disease 2023; 76:745 and Clin Infect Dis 2023; 76:750).",
        "Longer durations of therapy, e.g., 10-14 days, may be appropriate in certain circumstances:",
        "Infections caused by more resistant pathogens (e.g., Pseudomonas, Acinetobacter, Stenotrophomonas, or other multidrug-resistant pathogens), particularly in patients with underlying ARDS or significant structural lung disease",
        "Severely immunocompromised hosts (e.g. recent organ transplantation or treatment for rejection within 3 months, congenital immunodeficiency, etc.).",
        "Presence of complications such as bacteremia (e.g., MRSA or MSSA pneumonia with bacteremia probably should be treated for 4 weeks) or empyema.",
        "Delayed improvement of clinical, radiologic, and/or laboratory parameters.",
        "Alternatively, can trend serum procalcitonin levels"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Risk factors for MDR organisms:",
        "Antimicrobial therapy in preceding 90 days. Current hospitalization of 5 days or more.",
        "Septic shock at time of VAP",
        "Acute renal replacement therapy prior to onset of VAP.",
        "Antibiotic resistance prevalent in the community or specific hospital unit",
        "The empiric regimen of choice may vary based on local prevalence and susceptibility of pathogens, known prior colonization with MDR organisms, prior treatment history, severity of illness.",
        "Improved outcome when at least one agent is active in vitro against the responsible pathogen; if MDR pathogens are suspected, initial coverage should be broad and then narrowed once culture and susceptibility results become available.",
        "2016 IDSA Guidelines: Clin Infect Dis 63:e61, 2016 (full manuscript); executive summary: Clin Infect Dis 63:575, 2016.",
        "2017 European Guidelines: (Eur Respir J 2017; 50: 1700582)"
      ]
    }
  ]
}
